The Molecular Oncology Almanac: Assertion Details

Assertion: Sensitivity to Sunitinib (in Acute Myeloid Leukemia)
Preclinical

Somatic Variant: FLT3 p.K663Q (Missense)

Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.

Citations:

Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.